

1 **Title- Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer**
2 **disease brains**

3

4 **Authors**

5 Brenna C Novotny^{1,2,3,*}, Maria Victoria Fernandez^{1,2,3,*}, Ciyang Wang^{1,2,3,4}, John P Budde^{1,2,3},
6 Kristy Bergmann^{1,2,3}, Abdallah Eteleeb^{1,2,3}, Joseph Bradley⁴, Carol Webster^{1,2,3}, Curtis Ebl^{1,2,3},
7 Joanne Norton^{1,2,3}, Jen Gentsch^{1,2,3}, Umber Dube¹, Fengxian Wang^{1,2,3}, John C Morris^{2,5,6}, Randall
8 J Bateman^{2,5,6}, Richard J Perrin^{2,5,6,7}, Eric McDade⁶, Chengjie Xiong⁵, Jasmeer Chhatwal⁸,
9 Dominantly Inherited Alzheimer Network Study Group, Alzheimer's Disease Neuroimaging
10 Initiative⁹, Alzheimer's Disease Metabolomics Consortium¹⁰, Alison Goate¹¹, Martin Farlow¹²,
11 Peter Schofield¹³, Helena Chui¹⁴, Celeste M Karch^{1,2,3}, Bruno A Benitez^{1,2,3,†}, Carlos
12 Cruchaga^{1,2,3,5,†}, Oscar Harari^{1,2,3,5,†,‡}

13 **Affiliations**

14 ¹ Department of Psychiatry, Washington University School of Medicine (WUSM), St. Louis, MO,
15 USA

16 ² Hope Center for Neurological Disorders. Washington University School of Medicine, St. Louis,
17 MO, USA

18 ³ NeuroGenomics and Informatics Center, Washington University School of Medicine, St Louis,
19 MO, USA

20 ⁴ Division of Biology & Biomedical Sciences, Washington University in St. Louis, St. Louis, MO,
21 USA

22 ⁵ The Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University
23 School of Medicine, St. Louis, MO, USA

24 ⁶ Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA

25 ⁷ Department of Pathology and Immunology, Washington University School of Medicine, Saint
26 Louis, MO, USA

27 ⁸ Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston,
28 MA, USA

29 ⁹ Data used in preparation of this article were obtained from the Alzheimer's Disease
30 Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within

31 the ADNI contributed to the design and implementation of ADNI and/or provided data but did not
32 participate in analysis or writing of this report. A complete listing of ADNI investigators can be
33 found at: [http://adni.loni.usc.edu/wp-](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)
34 [content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)

35 ¹⁰ Data used in preparation of this article were generated by the Alzheimer's Disease
36 Metabolomics Consortium (ADMC). As such, the investigators within the ADMC provided data
37 but did not participate in analysis or writing of this report. A complete listing of ADMC
38 investigators can be found at: <https://sites.duke.edu/adnimetab/team/>

39 ¹¹ Icahn School of Medicine at Mount Sinai, New York, NY, USA

40 ¹² Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA

41 ¹³ Neuroscience Research Australia, Randwick, Sydney, NSW, Australia

42 ¹⁴ Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

43 * These authors contributed equally as first authors

44 † These authors contributed equally as senior authors

45

46 ‡ Corresponding author

47 Oscar Harari, PhD

48 Assistant Professor

49 Dept. of Psychiatry.

50 Washington University, School of Medicine

51 4444 Forest Park Ave.

52 Office 5587 - Campus Box 8134

53 St. Louis, MO, 63110

54 T: (314) 273-1862

55 Email: harario@wustl.edu

56

57 **Abstract**

58 The identification of multiple genetic risk factors for Alzheimer Disease (AD) provides evidence to
59 support that many pathways contribute to AD onset and progression. However, the metabolomic
60 and lipidomic profiles in carriers of distinct genetic risk factors are not fully understood. The
61 metabolome can provide a direct image of dysregulated pathways in the brain, including
62 information on treatment targets. In this study, we interrogate the metabolomic and lipidomic
63 signatures in the AD brain, including carriers of pathogenic variants in *APP*, *PSEN1*, and *PSEN2*
64 (autosomal dominant AD; ADAD), *APOE* ϵ 4 and *TREM2* risk variant carriers, and non-carrier
65 sporadic AD (sAD). We generated metabolomic and lipidomic data from parietal cortical tissue
66 from 366 participants with AD pathology and 26 cognitively unimpaired controls using the
67 Metabolon global metabolomics platform. We identified 133 metabolites associated with disease
68 status (FDR q -value<0.05). In sAD brains these include tryptophan betaine (b=-0.57) and N-
69 acetylputrescine (b=-0.14). Metabolites associated with sAD and ADAD include ergothioneine
70 (b=-0.21 and -0.26 respectively) and serotonin (b=-0.34 and -0.58, respectively). *TREM2* and
71 ADAD showed association with α -tocopherol (b=-0.12 and -0.12) and CDP-ethanolamine (b=-
72 0.13 and -0.10). β -citrylglutamate levels are associated with sAD, ADAD, and *TREM2* compared
73 to controls (b=-0.15; -0.22; and -0.29, respectively). Additionally, we identified a signature of 16
74 metabolites that is significantly altered between genetic groups (sAD vs. control $p = 1.05 \times 10^{-7}$,
75 ADAD vs. sAD $p = 3.21 \times 10^{-5}$) and is associated with Braak tau stage and disease duration. These
76 data are available to the scientific community through a public web browser
77 (<http://ngi.pub/Metabolomics>). Our findings were replicated in an independent cohort of 327
78 individuals.

79 **Keywords**

80 Autosomal dominant Alzheimer disease, *APP*, *PSEN1*, *PSEN2*, *APOE*, *TREM2*, metabolomics,
81 lipidomics, β -citrylglutamate

82

83 INTRODUCTION

84 Alzheimer disease (AD), the most common form of dementia, is a heterogeneous and complex
85 disease neuropathologically characterized by the accumulation of amyloid (A β) plaques and
86 neurofibrillary tangles in the brain. AD may develop as familial or sporadic. Recent advancements
87 in AD diagnosis and treatment could benefit from a comprehensive multi-omic approach to
88 studying diverse biological processes, including metabolism^{1,2}. Pathological changes in AD begin
89 decades before the diagnosis of AD³. Therefore, metabolomic changes linked to AD pathology
90 could precede disease onset and be highly informative for predictive models and preventative
91 medicine. Metabolic decline is one of the first physiological changes detected in patients with mild
92 cognitive impairment (MCI) due to AD⁴. Changes in lipid and energy metabolism are proven
93 hallmarks of AD, but there are also reports of impairments in neurotransmitter, urea cycle, purine,
94 polyamine, and bile acid metabolisms⁵. Current symptomatic treatments (cholinesterase inhibitors
95 and memantine) target deficits in neurotransmitters to minimize cognitive decline⁶. The
96 dysregulation of sphingolipids and glycerophospholipids in blood samples from the Alzheimer
97 Disease Neuroimaging Initiative (ADNI) and both blood and brain samples from the Baltimore
98 Longitudinal Study of Aging (BLSA) cohorts have been previously reported⁷⁻⁹. These metabolites
99 allowed discrimination between AD and controls with high accuracy, sensitivity, and specificity¹⁰.
100 Blood and brain endophenotype scores were then generated that summarized the relative
101 importance of each metabolite to the severity of AD pathology and disease progression.
102 Furthermore, Stamate et al. (2019) used machine learning classifiers to demonstrate that a panel
103 of plasma metabolites has the potential to match the area under the curve (AUC) of well-
104 established cerebrospinal fluid (CSF) biomarkers when used to classify AD vs. healthy
105 individuals¹¹. Pathway analysis with the top 20 predictive metabolites indicated that the nitrogen
106 pathway was overrepresented. Though much progress has been made in determining the specific
107 metabolic changes in biospecimens from AD patients, the metabolomic landscape has yet to be
108 fully understood.

109 AD is highly heritable and can be caused by autosomal dominant genetic variants in the amyloid
110 precursor protein (*APP*), presenilin-1 and -2 (*PSEN1* and *PSEN2*) genes, or associated with risk
111 factors in multiple other loci including apolipoprotein E (Apo E) and triggering receptor on myeloid
112 cells 2 (*TREM2*)¹²⁻¹⁴. The singularities of downstream effects of the complex AD genetic etiology
113 are currently poorly understood. Pathogenic genetic variants in *APP*, which is cleaved into A β by
114 β - and γ -secretase, cause altered production of A β . *PSEN1* and *PSEN2*, each crucial members
115 of the γ -secretase complex, can carry pathogenic variants resulting in increased cleavage of *APP*

116 into an A β isoform more prone to aggregation¹⁵. *TREM2* interacts with APOE, A β , and other lipids,
117 mediating the recruitment of microglia to A β plaques^{16,17}. Rare variants in the *TREM2* gene may
118 lead to impaired microglial function, contributing to AD pathology¹⁸. Apo E is a critical player in
119 lipid metabolism, transport, and homeostasis in the brain, and the $\epsilon 4$ allele of the *APOE* gene is
120 the main genetic risk factor for late-onset AD. Arnold et al. (2020) performed association analyses
121 of 139 serum metabolites in the ADNI cohort and observed that females carrying the *APOE* $\epsilon 4$
122 allele experience more significant impairment of mitochondrial energy production than males¹⁹.
123 These findings suggest that genetic risk factors contribute to AD pathology through distinct
124 mechanisms. However, the metabolomic changes associated with AD pathology and with most
125 genetic factors are currently unknown.

126 We sought to systematically investigate the metabolic signature of AD for carriers of the major
127 AD genetic risk factors. In this study, we have interrogated the metabolomic and lipidomic
128 signatures of carriers of pathogenic variants in *APP*, *PSEN1* or *PSEN2*, *APOE*, and *TREM2* risk
129 variant carriers and compared their profiles to symptomatic AD (non-genetic), presymptomatic
130 individuals with AD neuropathological change but no or minimal decline of cognition, and
131 cognitively unimpaired controls without AD neuropathology. Our analysis uncovered common
132 profiles altered across genetically categorized brains, and metabolites and lipids specific to the
133 distinct genetic factors.

134 MATERIALS & METHODS

135 Cohorts

136 WUSM

137 Archived fresh-frozen post-mortem parietal cortical tissue samples were obtained from the
138 Charles F. and Joanne Knight Alzheimer Disease Research Center Brain Bank (Knight ADRC)
139 and the Dominantly Inherited Alzheimer Network (DIAN) at Washington University School of
140 Medicine (WUSM). Samples were obtained with informed consent, and the study was approved
141 by the WUSM Institutional Review Board. Data available for these samples included age at AD
142 onset, age at death (AAD), gender, Clinical Dementia Rating® (CDR®)²⁰, *APOE* and *TREM2*
143 genotypes, ADAD variant status, and Braak stages for tau and A β . Samples were categorized
144 based on neuropathological and genetic information: neuropathological diagnosis of AD and
145 carrier of a pathogenic variant in any of the autosomal dominant genes (*APP*, *PSEN1*, *PSEN2*)
146 (autosomal dominant AD [ADAD], n=25), carriers of *TREM2* risk-variants (*TREM2*, n=21), no
147 known pathogenic variants (sAD, n=305), no clinical symptoms (Presymptomatic, n=15), and
148 brains with no or minimal neuropathological AD lesions identified through post-mortem
149 neurological examination (controls [CO], n=26) (**Table 1**). These cohorts have been described
150 previously^{21–29}. One participant in the control group showed elevated tau pathology (Braak tau
151 stage IV) but was classified as a control due to the absence of dementia (CDR 0) and lack of
152 amyloid pathology (Braak A β stage A). This individual's pathology is attributed to primary age-
153 related tauopathy (PART)^{30,31}.

154 ROSMAP

155 Data was generated by the Duke Metabolomics and Proteomics Shared Resource, a member of
156 the ADMC, using protocols published previously for blood samples^{19,32,33}; a custom protocol
157 developed for the brain samples can be found on Synapse at [syn10235609](https://www.synapse.org/Syn10235609). Serum (syn10235596)
158 and DLPFC (syn10235595) data from ROSMAP quantified on the Biocrates AbsoluteIDQ p180
159 platform were downloaded from Synapse in December 2020. The dorsolateral prefrontal cortex
160 (DLPFC) metabolomic data from the ROSMAP studies quantified on the Metabolon Precision
161 Metabolomics platform and preprocessed by the ADMC as described in³⁴ were downloaded from
162 Synapse in July 2021 (syn25878459). Details of the ROSMAP study design and methods have
163 been described previously^{35,36}. Disease status was determined based on a combination of
164 neuropathological and cognitive metrics. Sporadic AD was defined as individuals with a CERAD
165 assessment of “definite AD” with any Braak tau stage, or “probable AD” with Braak of at least IV.

166 Controls were defined by a CERAD of “possible AD” or “not AD” with Braak less than four. All AD
167 individuals have a clinical consensus diagnosis of cognitive impairment as defined by Schneider
168 et al. (2007), and controls have a consensus diagnosis of no cognitive impairment³⁷. From the
169 ROSMAP cohort, the following samples were analyzed: 36 sAD and 55 CO serum samples, 233
170 sAD and 94 CO DLPFC samples quantified with Metabolon, and 43 sAD and 23 CO DLPFC
171 samples quantified with Biocrates p180 (**Table 1**). For further analysis of the ROSMAP Metabolon
172 cohort, an additional group of 223 AD and 154 CO participants was considered, based on
173 consensus clinical diagnosis only (**Supplementary Table 1**).

174 ADNI

175 Data was generated by the Duke Metabolomics and Proteomics Shared Resource, a member of
176 the ADMC, using protocols published previously for blood samples^{19,32,33}. The ADNI1 and
177 ADNIGO/2 serum metabolomic data were obtained from the ADNI database (adni.loni.usc.edu)³³
178 via the ADNIMERGE package v0.0.1 (packaged March 2018, accessed December 2020)³⁸. The
179 ADNI was launched in 2003 as a public-private partnership led by Principal Investigator Michael
180 W. Weiner, MD. ADNI aims to test whether neuroimaging can be combined with clinical
181 assessment and other biological markers to measure the progression of mild cognitive impairment
182 (MCI) and early Alzheimer disease (AD). Additional information for the ADNI studies is available
183 at www.adni-info.org³⁹. The samples analyzed from ADNI cohorts were as follows: 184 sAD and
184 224 CO serum samples from the ADNI1 cohort, and 137 sAD and 181 CO serum samples from
185 the ADNIGO/2 cohort (**Table 1**).

186 **Metabolite Quantification**

187 Metabolon Precision Metabolomics™ Platform

188 Data from the Knight ADRC, DIAN, and one ROSMAP cohort were generated on the Metabolon
189 Precision Metabolomics platform. For the Knight ADRC and DIAN cohorts, 50mg frozen parietal
190 cortical tissue samples were used for metabolite quantification. Thirteen duplicate samples served
191 as technical replicates. The Metabolon Precision Metabolomics platform uses an ultrahigh
192 performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) system
193 (Metabolon, Inc., Morrisville, USA). The platform measured 880 metabolites for the WUSM
194 dataset and 1055 metabolites for the ROSMAP dataset. These metabolites are assigned to 111
195 pathways as classified by Metabolon, known as Sub Pathways. These Sub Pathways are
196 themselves classified into nine Super Pathways: amino acids, carbohydrates, cofactors and

197 vitamins, energy, lipids, nucleotides, peptides, xenobiotics, and partially characterized molecules
198 **(Supplementary Table 2).**

199 Biocrates AbsoluteIDQ® p180 Platform

200 The remaining ADNI and ROSMAP datasets were quantified by the Biocrates AbsoluteIDQ p180
201 platform, which measures approximately 180 metabolites using a combination of ultra-high
202 pressure liquid chromatography and flow-injection analysis coupled with mass spectrometry
203 (Biocrates Life Science AG, Innsbruck, Austria). Of these 180 metabolites, 85 could be matched
204 with those quantified by Metabolon based on Human Metabolome Database Identifier (HMDB ID)
205 **(Supplementary Table 2).**

206 **Quality Control**

207 Knight ADRC and DIAN Cohorts

208 The first step in the quality control process was to verify the quantification platform's consistency
209 by evaluating the technical replicates' reproducibility. We chose the 154 metabolites with no
210 missing values and a coefficient of variation greater than 0.3 to compare between replicate pairs
211 via Pearson's correlation. Each of the 13 replicate pairs showed a correlation above 0.9,
212 demonstrating a high level of consistency. The replicate pairs were then averaged for downstream
213 analysis. For each metabolite, if only one reading was missing from a replicate pair and the non-
214 missing value was in the bottom 10% of the metabolite's distribution, the non-missing value was
215 kept. This method assumes that the missing readings in such pairs were due to the metabolite
216 level being close to the detection limit rather than due to a technical error. Single non-missing
217 values in the top 90% of a metabolite's distribution were dropped.

218 Metabolon provided annotations for 815 of the 880 metabolites quantified analytes. The 65
219 remaining analytes were not assigned to known structural identities and were excluded from
220 further analyses. We identified 198 metabolites with missing readings in at least 20% of samples.
221 Before excluding these metabolites, Fisher's exact tests were performed to determine if any
222 showed differential missingness between sAD and CO, ADAD and CO, or ADAD and sAD. Those
223 that had significantly different missingness were tested using linear regression, corrected by AAD
224 and sex, to determine whether their non-missing readings were also significantly different in those
225 comparisons. Those metabolites that had more missing values and lower metabolite readings in
226 one status compared to another were rescued, assuming that their missingness was driven by a
227 biological effect rather than a technical artifact. In all, 10 metabolites were recovered using this
228 approach: 3-methyl-2-oxobutyrate, 4-hydroxyphenylpyruvate, acetylcholine, androsterone

229 sulfate, cysteinylglycine disulfide, gamma-glutamyl-epsilon-lysine, gamma-
230 glutamylphenylalanine, pregnenediol sulfate, serotonin, and tryptophan betaine. The missing
231 readings for these 10 metabolites were imputed with each metabolite's respective minimum
232 reading. The 188 remaining metabolites missing at least 20% of readings were excluded from the
233 dataset (**Supplementary Figure 1**).

234 Raw readings were log₁₀-transformed to better approximate a normal distribution. Outlier
235 readings (outside 1.5 x interquartile range) for each metabolite were excluded, and the mean of
236 each metabolite's distribution was adjusted to zero.

237 After the metabolite QC, 95% of samples were missing less than 5% of metabolite readings; the
238 maximum missingness for a sample was 11%. No samples were excluded due to the missingness
239 rate, and the remaining missing values were not imputed. Principal component analysis was then
240 performed on the scaled and imputed data provided by Metabolon to identify outlier samples using
241 the R function PCA from the FactoMineR package⁴⁰. Four outlier samples were excluded
242 (**Supplementary Figure 2**). The final dataset consisted of 627 metabolites measured in 392
243 samples (**Supplementary Table 3**).

244 Replication Datasets

245 We employed the above-described procedure to perform the data cleaning and QC of the ADNI
246 and ROSMAP datasets. Briefly, replicates were averaged, removing single readings above the
247 tenth percentile of the metabolite's distribution. Metabolites without assigned structural identities
248 and metabolites missing at least 20% of readings were removed, readings were log₁₀-
249 transformed, outlier readings were removed, and the mean of each metabolite's distribution was
250 adjusted to zero. For each dataset, samples missing greater than 20% of readings were excluded:
251 one from ROSMAP p180 brain, two from ROSMAP Metabolon brain, two from ADNI1, and one
252 from ADNIGO/2. Five metabolites with missingness higher than 20% were recovered from the
253 ROSMAP Metabolon cohort according to the procedure described above, considering
254 associations with AD for both the neuropathological and clinical diagnoses: saccharopine,
255 tryptophan betaine, memantine, retinol (Vitamin A) and 6-oxopiperidine-2-carboxylate. Missing
256 values for these metabolites were imputed with the metabolites' minimum readings. After QC,
257 the ADNI1 dataset included 149 metabolites in 408 samples, the ADNIGO/2 dataset included 157
258 metabolites in 318 samples, the ROSMAP serum dataset included 162 metabolites in 91 samples,
259 and the ROSMAP Metabolon brain dataset included 595 metabolites in 327 samples. The
260 ROSMAP p180 brain dataset consisted of 157 metabolites in 66 samples (**Table 1**).

261 **Statistical analyses**

262 Association analyses of metabolite abundance with disease status were conducted using linear
263 regression in R software version 3.6⁴¹. Metabolite levels were modeled by disease status (sAD,
264 ADAD, and TREM2) compared to CO, corrected by sex, AAD, and post-mortem interval (PMI).
265 Associations with *APOE* $\epsilon 4$ carrier status were also tested within the sAD status, corrected by the
266 same variables. AAD and PMI were chosen as covariates in the model due to their correlation
267 with the first principal component of the metabolites that passed QC ($p < 0.01$). When comparing
268 ADAD with CO, AAD was not included as it is collinear with ADAD status. Linear regression was
269 also used to test each metabolite's association with AAD in the sAD status group, correcting for
270 sex and PMI. The false discovery rate (FDR) was controlled using Benjamini-Hochberg correction
271 (R function `p.adjust`). The q -value threshold for significance was established as $q < 0.05$. To test
272 differences in effect size between groups, we employed an analysis of covariance (ANCOVA)
273 comparing the effects for metabolites in sAD and TREM2 relative to their effect in ADAD. We
274 performed additional ANCOVA tests with individuals matched by CDR (CDR = 3), tau (Braak tau
275 > 3), and A β (Braak A β = 3) to test whether the differences in effect sizes were influenced by
276 neuropathology.

277 We calculated the first principal component of readings for metabolites which were differentially
278 abundant in multiple groups, similar to the "eigengene" concept in the WGCNA package⁴². We
279 tested the differences in the *eigenmetabolite* profile between groups. We also tested for
280 association with CDR, Braak tau stage, and disease duration, defined as the difference of age at
281 disease onset (AAO) and AAD. The linear regression models were corrected for sex, PMI, and
282 AAD.

283 We conducted additional analyses in the ADNI and ROSMAP public metabolomics datasets to
284 follow up on our results. For the analyses in serum, PMI was not used as a covariate as it was
285 not applicable, and age at blood draw was used in the model rather than AAD. A meta-analysis
286 was also performed combining the serum data from the ADNI1, ADNIGO/2, and ROSMAP
287 datasets. The meta-analysis was carried out with the same linear model, pooling all 817 serum
288 samples: 357 sAD and 460 CO. Meta-analysis models were additionally corrected by study.

289 A heatmap was constructed using Metabolon's scaled and minimum-imputed metabolite readings
290 with the ComplexHeatmap⁴³ and circlize⁴⁴ R packages. Individuals were separated into status
291 groups (ADAD, sAD, TREM2, Presymptomatic, and CO), and the heatmap was additionally
292 annotated with CDR and Braak tau scores for each individual. Hierarchical clustering of

293 individuals was performed using the ward.D2 method in the Heatmap function from the
294 ComplexHeatmap package.

295 Pathway and network analyses were performed using MetaboAnalyst^{45,46} and IMPaLA pathway
296 over-representation analysis⁴⁷. HMDB IDs for 105 of the 133 significant metabolites could be
297 determined and input into MetaboAnalyst and IMPaLA. MetaboAnalyst matched 103 of those IDs
298 to its database, while IMPaLA matched 74 (**Supplementary Table 4**). Pathways were also
299 explored in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database⁴⁸⁻⁵⁰. The
300 source code of the scripts employed to QC, clean and analyze the data is available at [http://](http://github.com/HarariLab/Metabolomics)
301 github.com/HarariLab/Metabolomics.

302 **Pharmacological Analysis**

303 We obtained pharmacological data for the research participants to determine any potential
304 confounding effects of medications in our analyses. Longitudinal pharmacological data were
305 available for 297 research participants from the Knight ADRC cohort. The number of time points
306 (clinical assessment dates) for each participant ranged from one to 20 visits, with a mean of 3.9.
307 The mean number of years between the most recent clinical assessment and year of death was
308 2.8 ± 2.5 , with a range of 0-14 years. Drug group information and alternate medication names
309 were obtained from the KEGG Drug database⁴⁸⁻⁵⁰. To test for confounding medication effects, we
310 performed linear regression to test for association between medications and potentially affected
311 metabolites. We also repeated the association analyses, including only individuals who had not
312 been administered the medications within the five years preceding their death, to confirm that the
313 differential abundance was not influenced by medications.

314 **Web Browser**

315 Our results are available through a public browser at <http://ngi.pub/Metabolomics>. The browser
316 was created using R Shiny version 1.4.0⁵¹ and the shinydashboard⁵², shinydashboardPlus⁵³,
317 plotly⁵⁴, DT⁵⁵, shinyjs⁵⁶, htmlwidgets⁵⁷, RColorBrewer⁵⁸, kableExtra⁵⁹, and dplyr⁶⁰ R packages.
318 Source code is publicly available in the GitHub repository
319 <http://github.com/HarariLab/Metabolomics>.

320

321 RESULTS

322 Study Design

323 In this study, we performed a metabolomics analysis of parietal cortical tissue from participants
324 of the DIAN and Knight ADRC cohorts (**Figure 1**). We determined the metabolomic profile of
325 392 participants, including three AD genetic subgroups: autosomal dominant AD (ADAD),
326 carriers of risk variants in *TREM2* (TREM2), and sporadic AD (sAD). Detailed phenotypic
327 information included genetic risk factors, CDR, and Braak staging for tau and A β . Out of the 880
328 metabolites quantified, 627 passed quality control (**Supplementary Table 3**). We tested
329 differential abundance using linear models adjusted for AAD, sex, and PMI and compiled the
330 differentially abundant metabolites into a profile to distinguish between AD genetic groups. We
331 also conducted a pathway analysis with the significantly associated metabolites. To validate our
332 results further, we performed association analysis on a total of 393 brain samples and 817
333 serum samples from both the ROSMAP and ADNI cohorts.

334 Metabolite association analysis identifies differential β -citrylglutamate levels in sporadic 335 AD and ADAD

336 Association analysis indicated that the ADAD group had the most distinct brain metabolomics
337 profile (with 131 significant metabolites; **Supplementary Table 5**), whereas the profiles for
338 TREM2 and sAD cases showed a lower number of differentially abundant metabolites, with only
339 three (α -tocopherol, β -citrylglutamate, and CDP-ethanolamine) and five (β -citrylglutamate,
340 ergothioneine, serotonin, tryptophan betaine, and N-acetylputrescine) significant metabolites
341 respectively (**Figure 2a-d**). The Super Pathways represented in the ADAD-associated
342 metabolites were Amino Acids (48 metabolites), Carbohydrates (12), Cofactors and Vitamins (9),
343 Energy (2), Lipid (30), Nucleotide (12), Peptide (12), and Xenobiotics (6). We found that 99 of the
344 131 significant metabolites were independent of AAD (**Supplementary Table 6**).

345 Pathway analysis performed with these 131 metabolites indicated overrepresented pathways in
346 the categories of amino acid metabolism, which accounted for the most pathways, as well as
347 sphingolipid and vitamin metabolism (**Supplementary Tables 7 and 8**). We observed
348 perturbations in several amino acid metabolism pathways, including glutamate, glutathione,
349 tryptophan, lysine and histidine metabolisms. Perturbations in sphingolipid metabolism have been
350 identified previously as potential biomarkers for AD¹⁰. Altered amino acid metabolism has also
351 been reported in multiple metabolomic studies of the AD brain^{19,32,61}. The most notable amino acid
352 pathways in our analysis were glutamate, glutathione, and tryptophan metabolism. Abnormal
353 glutamate metabolism is known to cause excitotoxicity⁶², and alterations in glutathione

354 metabolism may contribute to oxidative damage and neuronal loss⁶³. Alterations in tryptophan
355 metabolism, especially serotonin imbalances, have also been previously noted in the AD
356 metabolome⁶⁴. We also observed perturbations in lysine and histidine metabolism pathways and
357 novel associations in vitamin pathways.

358 β -citrylglutamate (BCG) was the only metabolite significantly differentially abundant in all three
359 genetic groups. Zhao et al. (2019) showed that serum BCG levels were significantly affected by
360 the administration of fluoxetine, a commonly prescribed SSRI antidepressant⁶⁵. In our study, five
361 participants were documented as having taken fluoxetine at the time of their most recent clinical
362 assessment. Five sAD participants and one presymptomatic participant had taken fluoxetine
363 within the five years preceding their death (**Supplementary Table 9**). A binomial logistic
364 regression showed that BCG levels were not associated with fluoxetine use within the five years
365 preceding their death in individuals with sAD ($p = 0.98$). Furthermore, we repeated the linear
366 regression for sAD vs. CO, excluding the individuals who had taken fluoxetine in the past five
367 years, and did not observe a change in the association of BCG levels between sAD and CO (effect
368 = -0.15 , $q = 3.7 \times 10^{-2}$). AAD was not associated with lifetime usage of fluoxetine ($p = 0.83$), nor
369 were AAO ($p = 0.63$) or disease duration ($p = 0.15$).

370 ***APOE* $\epsilon 4$ carrier status shows nominal associations with metabolites**

371 In an association analysis of *APOE* $\epsilon 4$ carriers vs. non-carriers in the sAD group, none of the 627
372 metabolites tested were significantly associated after FDR correction, though 25 metabolites were
373 nominally significant ($p < 0.05$) (**Supplementary Table 10**).

374 **Follow-up in independent datasets**

375 We tested the differential abundance of metabolites in serum and DLPFC samples from the
376 ADNI1, ADNIGO/2, and ROSMAP cohorts to independently validate our results. For each of these
377 cohorts, metabolites were quantified using the Biocrates AbsoluteIDQ p180 platform, which we
378 found to have 85 metabolites in common with the Metabolon Precision Metabolomics platform.
379 Additionally, 379 DLPFC samples were analyzed from the ROSMAP cohort, quantified on the
380 Metabolon platform; in this dataset, 506 metabolites were in common with the Knight ADRC
381 cohort after QC. We identified 44 metabolites that were significantly differentially abundant with
382 consistent effect direction in our ADAD vs. CO analysis and at least one independent dataset.
383 Among the replicated metabolites were α -tocopherol, BCG, and serotonin (**Supplementary Table**
384 **11**).

385 Of the seven analytes that were significant in both serum and brain cohorts, distinct direction of
386 effect between tissue types was identified among five analytes. Specifically, 2-aminoadipate,
387 isoleucine, valine, glutamate, and tyrosine showed a positive effect in the ADAD samples and
388 ROSMAP sAD brains but showed a negative effect in the serum analyses. Similarly, Huo, et al.
389 (2020) observed opposite directions of effect for glycerophospholipids between brain and serum
390 in the ROSMAP cohort⁶⁶. Serotonin and 1-linoleoyl-2-arachidonoyl-GPC showed concordant
391 effects between the tissues, with lower abundance in ADAD and sAD than controls.

392 The replicated metabolites supported our previous pathway analysis findings. Components of
393 nicotinamide metabolism (trigonelline), vitamin A metabolism (retinol/Vitamin A), and tocopherol
394 metabolism (α -tocopherol/vitamin E), were replicated, supporting the role of vitamin pathways.
395 Asparagine, methionine, threonine, and tyrosine, all part of the gamma-glutamyl cycle, were found
396 in the replicated metabolites, along with serotonin of the tryptophan metabolism pathway. Finally,
397 BCG, glutamate, and N-acetyl-aspartyl-glutamate were each replicated, implicating the
398 dysregulation of glutamate metabolism.

399 Like the WUSM cohort, no metabolites were significant after correction when testing metabolite
400 associations for APOE ϵ 4 carriers vs. non-carriers. However, 23 were nominally significant ($p <$
401 0.05), of which none were replicated from the WUSM cohort (**Supplementary Table 10**).

402 **A metabolic profile associated with AD duration and Braak stage**

403 We sought to investigate whether ADAD, TREM2, and sAD showed a similar or more distinct
404 difference in their altered metabolomic profile. Thus, we selected the 17 metabolites that were
405 significantly associated in the ADAD brains (q -value <0.05) that also were nominally associated
406 in both the sAD and TREM2 when compared to controls (**Table 2**). Of these, ergothioneine,
407 serotonin, BCG, CDP-ethanolamine, and α -tocopherol were statistically significant after FDR
408 correction in sAD (ergothioneine, serotonin, and BCG) or TREM2 (BCG, CDP-ethanolamine, and
409 α -tocopherol) (**Table 2**). These five metabolites showed lower abundance in the AD groups as
410 compared to controls. This group of 17 metabolites was considered for the identification of a
411 metabolic profile differentiating between status groups. Serotonin was excluded from the profile
412 because the ADAD group was missing 17 of 25 readings for serotonin (68%). In the ROSMAP
413 Metabolon cohort, the differential abundance of nine out of the 16 remaining metabolites was
414 replicated after FDR correction: γ -glutamylthreonine, β -citrylglutamate, glutamate, N-
415 acetylglutamate, 1,5-anhydroglucitol, glutarate, CDP-choline, retinol, and α -tocopherol.
416 Additionally, aspartate, ergothioneine, 2-methylcitrate/homocitrate, and glycerophosphoinositol
417 were nominally significant, and 3-hydroxy-2-ethylpropionate did not pass QC.

418 We next compared the magnitude of the effects of the remaining 16 common metabolites across
419 the three genetic groups. The effect in ADAD tended to be greater than that of TREM2, which
420 was in turn greater than the effect in sAD (**Figure 3B**). An ANCOVA test showed that the relative
421 effects of sAD and TREM2 to ADAD were significantly different ($p = 4.37 \times 10^{-04}$). This difference
422 in effect was reproduced when individuals were matched by CDR ($p = 2.54 \times 10^{-02}$) as well as Braak
423 stage for Tau ($p = 1.18 \times 10^{-03}$) and A β ($p = 2.20 \times 10^{-03}$).

424 Among the 16 common metabolites across the three genetic groups, four were also associated
425 with AAD in a linear regression corrected for sex and PMI: 1,5-anhydroglucitol (1,5-AG),
426 glycerophosphoinositol, N-acetylglutamate, and retinol (vitamin A).

427 We then calculated the first principal component for these 16 metabolites to generate an
428 “eigenmetabolite” representing the metabolic profile for each individual⁴². The eigenmetabolite
429 was found to be associated with disease duration in sAD ($p = 1.86 \times 10^{-02}$), as well as Braak Tau
430 stage ($p = 4.17 \times 10^{-11}$) and CDR ($p = 4.23 \times 10^{-13}$) in the entire cohort, with a lower eigenmetabolite
431 value being associated with longer duration, higher Braak stage, and higher CDR.
432 Eigenmetabolite values were significantly different between status groups, with ADAD, TREM2,
433 and sAD having significantly lower eigenmetabolite values than CO and ADAD having significantly
434 lower values than sAD (**Figure 3C**). To validate these observations, 15 metabolites with available
435 data for the ROSMAP Metabolon dataset (all except 3-hydroxy-2-ethylpropionate) were used to
436 generate an eigenmetabolite profile for the ROSMAP participants. The eigenmetabolite was again
437 associated with disease duration ($p = 2.68 \times 10^{-02}$), but was not associated with Braak tau stage (p
438 = 0.38). Eigenmetabolite values were not significantly associated with sAD in the
439 neuropathological categorization ($p = 0.91$), but were associated with consensus clinical
440 diagnosis, with lower values observed in AD participants ($p = 2.73 \times 10^{-3}$) (**Figure 4**).

441 To visualize levels of the 16 metabolites between status groups in the WUSM cohort, a heatmap
442 was generated with the scaled and imputed metabolite readings from Metabolon (**Figure 3A**). A
443 group of 30 sAD individuals, identified by hierarchical clustering, with metabolite abundance
444 profiles not significantly different from the control group was selected for further analysis. For
445 these individuals, the eigenmetabolite was not significantly different from the control group in a
446 logistic regression correcting for AAD, sex, and PMI ($p = 0.66$). These individuals were classified
447 as Early-Stage AD (ESAD) after further logistic regression analysis of CDR, Braak tau, and
448 disease duration, correcting for the same variables. The ESAD group showed lower CDR (ESAD
449 = 1.67 ± 1.09 , sAD = 2.56 ± 0.84 , effect = -0.83, $p = 8.02 \times 10^{-6}$) and Braak Tau (ESAD = 4.05 ± 1.36 ,
450 sAD = 5.30 ± 1.06 , effect = -0.66, $p = 1.22 \times 10^{-4}$) compared to sAD. The ESAD individuals also

451 showed a shorter disease duration (ESAD = 7.97 ± 5.33 , sAD = 10.03 ± 4.61 , effect = -0.09 , $p =$
452 4.42×10^{-2}) than the rest of the sAD individuals.

453 To explore the relationship between this metabolic profile and disease progression,
454 presymptomatic individuals were also considered. The eigenmetabolite values for the
455 presymptomatic group were not significantly different from the CO and ESAD groups ($p = 0.18$
456 and $p = 0.06$, respectively) (**Figure 3C**). As expected, the presymptomatic status group showed
457 significantly lower CDR (effect = -7.52 , $p = 2.47 \times 10^{-03}$) than the ESAD group. However, the
458 presymptomatic group did not differ from ESAD in the Braak Tau stage ($p = 0.92$).

459 The super pathways associated with these 16 metabolites were mostly related to amino acid
460 metabolism (glutamate, arginine, lysine, glutathione, histidine, tryptophan), but phospholipid and
461 vitamin pathways were also identified. CDP-ethanolamine, CDP-choline, and
462 glycerophosphoinositol were associated with phospholipid metabolism, while α -tocopherol
463 (vitamin E), retinol (vitamin A), and nicotinamide (vitamin B3) were components of vitamin
464 metabolism.

465 Considering that three of the metabolites in the eigenmetabolite profile were vitamins: retinol
466 (vitamin A), α -tocopherol (vitamin E), and nicotinamide (vitamin B3), we also investigated
467 participants who had taken vitamin supplements to rule out any confounding association. Within
468 the five years preceding their deaths, 132 individuals took vitamin E supplements, 87 individuals
469 took vitamin A, and 101 individuals took vitamin B3 (**Supplementary Table 9**). When regressions
470 were repeated excluding individuals who took vitamin E supplements, we observed that all of the
471 associations remained significant in TREM2 ($p = 3.9 \times 10^{-04}$), ADAD ($p = 2.9 \times 10^{-05}$), and sAD ($p =$
472 2.9×10^{-04}). Similarly, excluding participants taking vitamin A supplements did not affect the
473 association of retinol with any genetic group (ADAD $p = 6.11 \times 10^{-04}$, AD $p = 1.40 \times 10^{-02}$, TREM2 p
474 $= 4.75 \times 10^{-02}$). When participants who took vitamin B3 were excluded, ADAD and TREM2 were
475 still nominally associated with nicotinamide (ADAD $p = 9.4 \times 10^{-03}$, TREM2 $p = 3.7 \times 10^{-02}$), however,
476 sAD was no longer associated ($p = 0.11$). Removing nicotinamide from the eigenmetabolite did
477 not affect the eigenmetabolite association with disease duration (effect = -0.052 , $p = 1.75 \times 10^{-02}$),
478 CDR (effect = -0.65 , $p = 4.49 \times 10^{-14}$), or Braak tau (effect = -0.57 , $p = 6.75 \times 10^{-12}$).

479 **Web Browser**

480 The browser facilitates exploration of our analyses and further investigation into individual
481 metabolites by integrating metadata with visualizations of our results. The browser has two main
482 pages, or tabs. The first displays a table including metadata on each metabolite that passed our

483 QC process, along with its effect, p -value, and q -value for each comparison discussed here. The
484 table allows the user to select a metabolite, which displays the distribution of the selected
485 metabolite's readings across disease statuses. Links are also provided to the PubChem
486 (<https://pubchem.ncbi.nlm.nih.gov/>)⁶⁷ and Human Metabolome Database (www.hmdb.ca)^{46,68}
487 webpages if the IDs are available. The second tab displays volcano plots for each regression,
488 with q -values less than 0.05 highlighted. Again, the user may select a metabolite on the volcano
489 plot to view its reading distributions among statuses and display further information and links.

490 DISCUSSION

491 In this study, we have performed a metabolomics analysis of parietal cortical tissue from
492 participants of the DIAN and Knight ADRC cohorts. We have characterized the metabolomic
493 profile of three genetically defined AD subgroups including ADAD, carriers of risk variants in
494 TREM2, and sAD. We have analyzed the detailed phenotypic information available for these
495 brains, including genetic risk factors and clinical, pharmacological, and neuropathological
496 variables.

497 We found a significantly different metabolic profile in ADAD patients from that of healthy
498 individuals, with 131 significant metabolites linked to ADAD, altering multiple pathways including
499 the γ -glutamyl cycle, tRNA charging, and aminoacyl-tRNA biosynthesis (**Supplementary Tables**
500 **7 and 8**). The parietal cortex of ADAD individuals has been reported to have a higher burden of
501 neurofibrillary tangles (NFT) than that of sAD individuals⁶⁹. Accordingly, the metabolic profiles of
502 TREM2 and sAD showed fewer differences than ADAD from that of healthy individuals, and of
503 the two only sAD showed metabolite differences unique to its category (tryptophan betaine and
504 N-acetylputrescine). Tryptophan betaine is an N-methylated form of tryptophan, which is the
505 serotonin precursor and has been found de-regulated in MCI-AD⁷⁰. N-acetylputrescine is an
506 acetyl-CoA-ated putrescine and a GABA precursor that was found to build up in stable MCI but
507 not in AD, where putrescine is preferentially metabolized to other polyamines⁷¹. We also observe
508 depleted N-acetylputrescine levels in sAD in our data (**Supplementary Figure 3**) which supports
509 previously reported findings of lower GABA levels in AD⁷².

510 Among the metabolites identified as differentially abundant in at least one group were BCG, α -
511 tocopherol, and ergothioneine. Each of these metabolites showed lower concentrations in an AD
512 subgroup compared to control. BCG acts as an iron carrier to activate aconitase activity⁷³. We
513 observed that BCG had the lowest abundance in ADAD, again followed by TREM2 and sAD. This
514 observation could be associated with a lower activation of aconitase and lower energetic
515 metabolism. BCG is also a component of glutamate metabolism, and BCG levels can be
516 increased by the selective serotonin reuptake inhibitor (SSRI) fluoxetine⁶⁵. BCG levels in our
517 cohort were not significantly associated with fluoxetine administration, indicating that the
518 association of BCG and AD in the three genetic groups is not driven by fluoxetine usage. Within
519 the vitamin pathway, α -tocopherol (vitamin E) was differentially abundant in both TREM2 and
520 ADAD vs CO, and vitamin E supplementation in participants did not affect this association.
521 Vitamin E is a powerful antioxidant that aids the immune system and keeps blood clots from
522 forming⁷⁴⁻⁷⁶. This finding complements our observation of lower BCG in sAD cases. Reduction

523 of aconitase activity due to oxidative stress in aging could be exacerbated in AD by lower levels
524 of antioxidants such as vitamin E. This could lead to less energetic metabolism activation overall.
525 Ergothioneine was also observed at lower levels in sAD and ADAD cases compared to controls.
526 Ergothioneine is a naturally occurring amino acid and thiourea derivative of histidine produced by
527 fungi, which has antioxidant and anti-inflammatory properties^{77,78}. The main source of
528 ergothioneine in humans is diet; it accumulates in erythrocytes and crosses the blood–brain
529 barrier⁷⁹. However, its physiological role in humans is not known. Ergothioneine blood levels in
530 humans decline with age and decline faster in individuals with cognitive impairment compared to
531 age-matched individuals with no cognitive impairment⁸⁰. In mice treated with
532 intracerebroventricular injection of A β 1-40, ergothioneine protected against loss of memory and
533 learning abilities⁸¹.

534 In addition to BCG, α -tocopherol, and ergothioneine, we identified eight metabolites in the
535 Vitamins pathway that were significant after FDR correction in ADAD vs healthy individuals and
536 significant before correction in the AD vs CO, TREM2 vs CO, and ROSMAP brain analyses. Four
537 of these (2-aminoadipate, serotonin, tryptophan and tyrosine) were also significant in the serum
538 meta-analysis and are important neurotransmitters.

539 Neurotransmitters, especially serotonin, have been shown to play a role in processing APP and
540 reducing generation of A β ₄₂ through activation of the ERK signaling cascade⁸². In our study,
541 serotonin levels were significantly decreased in sAD and ADAD compared to control, and
542 nominally decreased in TREM2. This effect was replicated in independent datasets of both serum
543 and DLPFC tissue. SSRIs, which increase serotonin levels in the brain, show promise for
544 reduction of A β accumulation in both the brain and CSF. Studies in APP/PS1 transgenic mice
545 showed that the SSRI citalopram caused a 50% reduction in brain amyloid plaque load, and
546 escitalopram, citalopram's S-isomer, reduced interstitial fluid A β by 25%^{82,83}. A controlled clinical
547 trial of cognitively normal adults showed that escitalopram could decrease CSF A β ₄₂ levels in
548 humans, with a difference of 11.1% between the control and treatment groups⁸⁴. Our results
549 corroborate the association of low serotonin with AD, and suggest that this effect, and potentially
550 the benefit of serotonin modulation via SSRIs, spans all three genetic groups.

551 Our discovery dataset identified a set of 16 metabolites whose first principal component, or
552 eigenmetabolite, was distinct between the AD groups and healthy individuals, and between sAD
553 and ADAD. The effects for these metabolites were greatest in ADAD, followed by TREM2 and
554 sAD. The eigenmetabolite was additionally associated with CDR, Braak tau stage, and disease
555 duration. The association with disease duration was validated in an independent dataset using 15

556 of the 16 metabolites. We also evaluated the performance of these 16 metabolites in a group of
557 presymptomatic individuals and observed that this group showed a similar profile to that of healthy
558 individuals. In addition, we identified a set of sAD cases (Early-Stage AD/ESAD) with a metabolic
559 profile close to that of the healthy individuals. Further examination of these individuals revealed
560 significantly lower CDR and Braak Tau scores than the rest of sAD individuals. The
561 presymptomatic and ESAD groups showed no significant difference in the metabolic
562 eigenmetabolite or Braak tau but significantly different CDR. Furthermore, ADAD individuals,
563 known to have an earlier age at onset and higher NFT burden, showed a greater effect for these
564 metabolites. Together, these observations suggest that the metabolic profile could be driven by
565 tau pathology and implicated in disease duration.

566 Spermidine was negatively associated with age in sAD and showed increased levels in sAD in
567 the ADNIGO/2 dataset compared to control (**Supplementary Tables 5 and 6**). However, we did
568 not find it associated with any genetic group in the Knight ADRC dataset. Putrescine was
569 significantly decreased in sAD before correction (**Supplementary Table 5**). N-acetylputrescine,
570 a putrescine derivative, was significantly decreased in the sAD group compared to control and
571 significantly decreased before FDR correction in TREM2. Schroeder, et al. (2021) found that
572 polyamines, particularly spermidine, improved cognition in mice by enhancing mitochondrial
573 function through hypusination of eukaryotic translation initiation factor 5A (eIF5A)⁸⁵. Liang, et al.
574 (2021) also showed that eIF5a activity decreased with age in fly models, and that spermidine
575 supplementation could improve mitochondrial function⁸⁶.

576 This study identified differences in metabolite abundance both specific to and common between
577 genetically defined AD subgroups. We replicated our main findings in three independent datasets.
578 Differences in the levels of common metabolites allow us to generate a metabolic profile
579 associated with disease duration, CDR, and Braak tau stage and that further identified a subset
580 of AD cases with a profile similar to CO (ESAD). Metabolomics of the brain can identify metabolic
581 signatures specific to AD genetic subgroups. These metabolites may support the creation of
582 “metabolomics scores” to assess disease status. Limitations of our study include the sample size
583 of some of the genetic groups, e.g. TREM2. As such, in future studies we would like to increase
584 the sample size of our brain-sourced dataset. We were unable to find associations with Braak A β
585 stage possibly because scores are unavailable for many participants. Direct replication of our
586 results in ADAD individuals was unachievable due to a lack of independent ADAD datasets.
587 Unlike previous studies, we did not find significant associations between *APOE* $\epsilon 4$ carriers and
588 non-carriers in cases of sporadic AD. In addition, our ability to replicate findings in other tissues,

589 such as blood serum, was possibly limited due to different platforms used by other studies. In
590 future studies we will extend our analysis to serum metabolomics data and seek replication of our
591 findings to facilitate further identification of novel biomarkers for AD.

592

593 **Data availability**

594 Metabolomics data from the Knight ADRC donors generated for this study are available at the
595 NIAGADS and can be accessed at <https://www.niagads.org/knight-adrc-collection>. Data
596 generated from the DIAN cohort can be requested at [https://dian.wustl.edu/our-research/for-](https://dian.wustl.edu/our-research/for-investigators/diantu-investigator-resources/dian-tu-biospecimen-request-form/)
597 [investigators/diantu-investigator-resources/dian-tu-biospecimen-request-form/](https://dian.wustl.edu/our-research/for-investigators/diantu-investigator-resources/dian-tu-biospecimen-request-form/). We have
598 accessed data from the ADNI (<https://adni.loni.usc.edu>, accessed 18 December, 2020), and
599 ROSMAP (<https://synapse.org/#!/Synapse:syn26007829>, accessed 18 December, 2020 and
600 <https://synapse.org/#!/Synapse:syn26007830>, accessed 30 July, 2021). Additional phenotypic
601 data for the ROSMAP studies is available through the Rush AD Center Resource Sharing Hub
602 (<https://www.radc.rush.edu>).

603

604 **Funding**

605 This work was possible thanks to the following governmental grants from the National institute of
606 Health: NIA R01AG057777, RO1AG057777-02S1, K99AG061281, P30AG066444,
607 P01AGO26276, NINDS R01NS118146 (BAB), R01AG044546 (CC), P01AG003991 (CC, JCM),
608 RF1AG053303 (CC), RF1AG058501 (CC), U01AG058922 (CC), and the Chan Zuckerberg
609 Initiative (CZI). O.H. is an Archer Foundation Research Scientist.

610 This work was supported by access to equipment made possible by the Hope Center for
611 Neurological Disorders, the NeuroGenomics and Informatics Center (NGI:
612 <https://neurogenomics.wustl.edu/>) and the Departments of Neurology and Psychiatry at
613 Washington University School of Medicine.

614 **Acknowledgements**

615 We thank contributors who collected samples used in this study and patients and their families,
616 whose help and participation made this work possible.

617 Dominantly Inherited Alzheimer Network (DIAN) resources

618 Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer
619 Network (DIAN, U19AG032438) funded by the National Institute on Aging (NIA),the Alzheimer's
620 Association (SG-20-690363-DIAN), the German Center for Neurodegenerative Diseases (DZNE),
621 Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and
622 Development Grants for Dementia from Japan Agency for Medical Research and Development,
623 AMED, and the Korea Health Technology R&D Project through the Korea Health Industry
624 Development Institute (KHIDI), Spanish Institute of Health Carlos III (ISCIII), Canadian Institutes
625 of Health Research (CIHR), Canadian Consortium of Neurodegeneration and Aging, Brain
626 Canada Foundation, and Fonds de Recherche du Québec – Santé. This manuscript has been
627 reviewed by DIAN Study investigators for scientific content and consistency of data interpretation
628 with previous DIAN Study publications. We acknowledge the altruism of the participants and their
629 families and contributions of the DIAN research and support staff at each of the participating sites
630 for their contributions to this study.

631 DIAN Study Group

632 Sarah Adams, Ricardo Allegri, Aki Araki, Nicolas Barthelemy, Randall Bateman, Jacob
633 Bechara, Tammie Benzinger, Sarah Berman, Courtney Bodge, Susan Brandon, William (Bill)
634 Brooks, Jared Brosch, Jill Buck, Virginia Buckles, Kathleen Carter, Lisa Cash, Charlie Chen,

635 Jasmeer Chhatwal, Patricio Chrem, Jasmin Chua, Helena Chui, Carlos Cruchaga, Gregory S
636 Day, Chrismary De La Cruz, Darcy Denner, Anna Diffenbacher, Aylin Dincer, Tamara Donahue,
637 Jane Douglas, Duc Duong, Noelia Egido, Bianca Esposito, Anne Fagan, Marty Farlow, Becca
638 Feldman, Colleen Fitzpatrick, Shaney Flores, Nick Fox, Erin Franklin, Nelly Friedrichsen, Hisako
639 Fujii, Samantha Gardener, Bernardino Ghetti, Alison Goate, Sarah Goldberg, Jill Goldman, Alyssa
640 Gonzalez, Brian Gordon, Susanne Gräber-Sultan, Neill Graff-Radford, Morgan Graham, Julia
641 Gray, Emily Gremminger, Miguel Grilo, Alex Groves, Christian Haass, Lisa Häsler, Jason
642 Hassenstab, Cortaiga Hellm, Elizabeth Herries, Laura Hoechst-Swisher, Anna Hofmann, David
643 oltzman, Russ Hornbeck, Yakushev Igor, Ryoko Ihara, Takeshi Ikeuchi, Snezana Ikonovic,
644 Kenji Ishii, Clifford Jack, Gina Jerome, Erik Johnson, Mathias Jucker, Celeste Karch, Stephan
645 Käser, Kensaku Kasuga, Sarah Keefe, William (Bill) Klunk, Robert Koeppe, Deb Koudelis, Elke
646 Kuder-Buletta, Christoph Laske, Allan Levey, Johannes Levin, Yan Li, Oscar Lopez, Jacob Marsh,
647 Rita Martinez, Ralph Martins, Neal Scott Mason, Colin Masters, Kwasi Mawuenyega, Austin
648 McCullough, Eric McDade, Arlene Mejia, Estrella Morenas-Rodriguez, John Morris, James
649 MountzMD, Cath Mummery, Neelesh Nadkarni, Akemi Nagamatsu, Katie Neimeyer, Yoshiki
650 Niimi, James Noble, Joanne Norton, Brigitte Nuscher, Antoinette O'Connor, Ulricke Obermüller,
651 Riddhi Patira, Richard Perrin, Lingyan Ping, Oliver Preische, Alan Renton, John Ringman,
652 Stephen Salloway, Peter Schofield, Michio Senda, Nick Seyfried, Kristine Shady, Hiroyuki
653 Shimada, Wendy Sigurdson, Jennifer Smith, Lori Smith, Beth Snitz, Hamid Sohrabi, Sochenda
654 Stephens, Kevin Taddei, Sarah Thompson, Jonathan Vöglein, Peter Wang, Qing Wang, Elise
655 Weamer, Chengjie Xiong, Jinbin Xu, Xiong Xu

656 Alzheimer's Disease Metabolomics Consortium (ADMC)

657 The results published here are in whole or in part based on data obtained from the AD Knowledge
658 Portal (<https://adknowledgeportal.org>). Metabolomics data is provided by the Alzheimer's Disease
659 Metabolomics Consortium (ADMC) and funded wholly or in part by the following grants and
660 supplements thereto: NIA R01AG046171, RF1AG051550, 3U01AG024904-09S4,
661 RF1AG057452, R01AG059093, RF1AG058942, U01AG061359, U19AG063744 and FNIH:
662 #DAOU16AMPA awarded to Dr. Kaddurah-Daouk at Duke University in partnership with a large
663 number of academic institutions. As such, the investigators within the ADCM, not listed specifically
664 in this publication's author's list, provided data along with its pre-processing and prepared it for
665 analysis, but did not participate in analysis or writing of this manuscript. A complete listing of
666 ADCM investigators can be found at: <https://sites.duke.edu/adnimetab/team/>.

667

668 ADNI

669 Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging
670 Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department
671 of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on
672 Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous
673 contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery
674 Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir,
675 Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F.
676 Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare;
677 IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson &
678 Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co.,
679 Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis
680 Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical
681 Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing
682 funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the
683 Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the
684 Northern California Institute for Research and Education, and the study is coordinated by the
685 Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data
686 are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

687 ROSMAP

688 Study data were provided by the Rush Alzheimer's Disease Center, Rush University Medical
689 Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161
690 (ROS), R01AG15819 (ROSMAP; genomics and RNAseq), R01AG17917 (MAP), R01AG30146,
691 R01AG36042 (5hC methylation, ATACseq), RC2AG036547 (H3K9Ac), R01AG36836 (RNAseq),
692 R01AG48015 (monocyte RNAseq) RF1AG57473 (single nucleus RNAseq), U01AG32984
693 (genomic and whole exome sequencing), U01AG46152 (ROSMAP AMP-AD, targeted
694 proteomics), U01AG46161 (TMT proteomics), U01AG61356 (whole genome sequencing,
695 targeted proteomics, ROSMAP AMP-AD), the Illinois Department of Public Health (ROSMAP),
696 and the Translational Genomics Research Institute (genomic). Additional phenotypic data can be
697 requested at www.radc.rush.edu. Study data were provided through NIA grant 3R01AG046171-
698 02S2 awarded to Rima Kaddurah-Daouk at Duke University, based on specimens provided by
699 the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, where data
700 collection was supported through funding by NIA grants P30AG10161, R01AG15819,

701 R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department
702 of Public Health, and the Translational Genomics Research Institute.

703 Additional Acknowledgements

704 We would like to pay our gratitude and respects to our friend and collaborator, Jorge Bahena.
705 Jorge was a remarkable scientist and respected colleague who earned his master's degree in
706 biostatistics from Washington University School of Medicine, and passed away in October 2021
707 as a doctoral student at Vanderbilt University. His valuable contributions to this and many other
708 endeavors will not be forgotten.

709 **Financial disclosures**

710 CC receives research support from: Biogen, Eisai, Alector and Parabon. The funders of the study
711 had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in
712 the decision to submit the paper for publication. CC is a member of the advisory board of Vivid
713 genetics, Halia Therapeutics and ADx Healthcare.

714

715 References

- 716 1. Zhao, N. *et al.* Alzheimer's risk factors age, APOE genotype, and sex drive distinct
717 molecular pathways. *Neuron* **106**, 727 (2020).
- 718 2. Badhwar, A. *et al.* A multiomics approach to heterogeneity in Alzheimer's disease:
719 focused review and roadmap. *Brain* **143**, 1315 (2020).
- 720 3. Holtzman, D. M., Morris, J. C. & Goate, A. M. Alzheimer's disease: the challenge of the
721 second century. *Sci. Transl. Med.* **3**, (2011).
- 722 4. Pagani, M. *et al.* Early identification of MCI converting to AD: a FDG PET study. *Eur. J.*
723 *Nucl. Med. Mol. Imaging* **44**, 2042–2052 (2017).
- 724 5. González-Domínguez, R., Sayago, A. & Fernández-Recamales, Á. Metabolomics in
725 Alzheimer's disease: The need of complementary analytical platforms for the
726 identification of biomarkers to unravel the underlying pathology. *J. Chromatogr. B* **1071**,
727 75–92 (2017).
- 728 6. Yiannopoulou, K. G. & Papageorgiou, S. G. Current and Future Treatments in Alzheimer
729 Disease: An Update. *J. Cent. Nerv. Syst. Dis.* **12**, 117957352090739 (2020).
- 730 7. Ferrucci, L. The Baltimore Longitudinal Study of Aging (BLSA): a 50-year-long journey
731 and plans for the future. *J. Gerontol. A. Biol. Sci. Med. Sci.* **63**, 1416–1419 (2008).
- 732 8. Mueller, S. G. *et al.* The Alzheimer's disease neuroimaging initiative. *Neuroimaging Clin.*
733 *N. Am.* **15**, 869–877 (2005).
- 734 9. Shock, N. W. *et al.* *Normal Human Aging: The Baltimore Longitudinal Study on Aging.*
735 (1984).
- 736 10. Varma, V. R. *et al.* Brain and blood metabolite signatures of pathology and progression in
737 Alzheimer disease: A targeted metabolomics study. *PLOS Med.* **15**, e1002482 (2018).
- 738 11. Stamate, D. *et al.* A metabolite-based machine learning approach to diagnose Alzheimer-
739 type dementia in blood: Results from the European Medical Information Framework for
740 Alzheimer disease biomarker discovery cohort. *Alzheimer's Dement. Transl. Res. Clin.*
741 *Interv.* **5**, 933–938 (2019).
- 742 12. Karch, C. M. & Goate, A. M. Alzheimer's disease risk genes and mechanisms of disease
743 pathogenesis. (2014) doi:10.1016/j.biopsych.2014.05.006.
- 744 13. Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional

- 745 pathways influencing Alzheimer's disease risk. *Nat. Genet.* 2019 513 **51**, 404–413
746 (2019).
- 747 14. Tan, M.-S. *et al.* Associations of Alzheimer's disease risk variants with gene expression,
748 amyloidosis, tauopathy, and neurodegeneration. *Alzheimer's Res. Ther.* 2021 131 **13**, 1–
749 11 (2021).
- 750 15. Haass, C., Kaether, C., Thinakaran, G. & Sisodia, S. Trafficking and Proteolytic
751 Processing of APP. *Cold Spring Harb. Perspect. Med.* **2**, (2012).
- 752 16. Zhao, Y. *et al.* TREM2 Is a Receptor for β -Amyloid that Mediates Microglial Function.
753 *Neuron* **97**, 1023-1031.e7 (2018).
- 754 17. Zhong, L. *et al.* Amyloid-beta modulates microglial responses by binding to the triggering
755 receptor expressed on myeloid cells 2 (TREM2). *Mol. Neurodegener.* **13**, (2018).
- 756 18. Ulland, T. K. & Colonna, M. TREM2 — a key player in microglial biology and Alzheimer
757 disease. *Nat. Rev. Neurol.* 2018 1411 **14**, 667–675 (2018).
- 758 19. Arnold, M. *et al.* Sex and APOE ϵ 4 genotype modify the Alzheimer's disease serum
759 metabolome. *Nat. Commun.* **11**, (2020).
- 760 20. Morris, J. C. The clinical dementia rating (cdr): Current version and scoring rules.
761 *Neurology* **43**, 2412–2414 (1993).
- 762 21. Coats, M. & Morris, J. C. Antecedent biomarkers of Alzheimer's disease: the adult
763 children study. *J. Geriatr. Psychiatry Neurol.* **18**, 242–4 (2005).
- 764 22. Bateman, R. J. *et al.* Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's
765 Disease. *N. Engl. J. Med.* **367**, 795 (2012).
- 766 23. Berg, L. *et al.* Clinicopathologic Studies in Cognitively Healthy Aging and Alzheimer
767 Disease: Relation of Histologic Markers to Dementia Severity, Age, Sex, and
768 Apolipoprotein E Genotype. *Arch. Neurol.* **55**, 326–335 (1998).
- 769 24. Yang, C. *et al.* Genomic atlas of the proteome from brain, CSF and plasma prioritizes
770 proteins implicated in neurological disorders. *Nat. Neurosci.* **24**, 1302–1312 (2021).
- 771 25. Dube, U. *et al.* An atlas of cortical circular RNA expression in Alzheimer disease brains
772 demonstrates clinical and pathological associations. *Nat. Neurosci.* **22**, 1903 (2019).
- 773 26. Del-Aguila, J. L. *et al.* A single-nuclei RNA sequencing study of Mendelian and sporadic
774 AD in the human brain. *Alzheimers. Res. Ther.* **11**, (2019).

- 775 27. Del-Aguila, J. L. *et al.* TREM2 brain transcript-specific studies in AD and TREM2 mutation
776 carriers. *Mol. Neurodegener.* **14**, (2019).
- 777 28. Jiang, S. *et al.* Integrative system biology analyses of CRISPR-edited iPSC-derived
778 neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP.
779 *Transl. Psychiatry* **8**, 265 (2018).
- 780 29. Li, Z. *et al.* Genetic variants associated with Alzheimer's disease confer different cerebral
781 cortex cell-type population structure. *Genome Med.* **10**, (2018).
- 782 30. Crary, J. F. *et al.* Primary age-related tauopathy (PART): a common pathology associated
783 with human aging. *Acta Neuropathol.* **128**, 755 (2014).
- 784 31. Hickman, R. A., Flowers, X. E. & Wisniewski, T. Primary Age-Related Tauopathy (PART):
785 Addressing the Spectrum of Neuronal Tauopathic Changes in the Aging Brain. *Curr.*
786 *Neurol. Neurosci. Rep.* **20**, 39 (2020).
- 787 32. Toledo, J. B. *et al.* Metabolic network failures in Alzheimer's disease: A biochemical
788 road map. *Alzheimer's Dement.* **13**, 965–984 (2017).
- 789 33. St John-Williams, L. *et al.* Targeted metabolomics and medication classification data from
790 participants in the ADNI1 cohort. *Sci. Data* **4**, (2017).
- 791 34. Batra, R. *et al.* The landscape of metabolic brain alterations in Alzheimer's disease.
792 *bioRxiv* 2021.11.15.468698 (2021) doi:10.1101/2021.11.15.468698.
- 793 35. Bennett, D. A. *et al.* Neuropathology of older persons without cognitive impairment from
794 two community-based studies. *Neurology* **66**, 1837–1844 (2006).
- 795 36. Bennett, D. A., Schneider, J. A., Arvanitakis, Z. & Wilson, R. S. OVERVIEW AND
796 FINDINGS FROM THE RELIGIOUS ORDERS STUDY. *Curr. Alzheimer Res.* **9**, 628
797 (2012).
- 798 37. JA, S., Z, A., W, B. & DA, B. Mixed brain pathologies account for most dementia cases in
799 community-dwelling older persons. *Neurology* **69**, 2197–2204 (2007).
- 800 38. Team, the A. ADNIMERGE: Alzheimer's Disease Neuroimaging Initiative. R package
801 version 0.0.1 (2018).
- 802 39. Saykin, A. J. *et al.* Alzheimer's Disease Neuroimaging Initiative biomarkers as
803 quantitative phenotypes: Genetics core aims, progress, and plans. *Alzheimer's Dement.*
804 **6**, 265–273 (2010).

- 805 40. Lê, S., Josse, J. & Husson, F. FactoMineR: An R package for multivariate analysis. *J.*
806 *Stat. Softw.* **25**, 1–18 (2008).
- 807 41. R Core Team. R: A language and environment for statistical computing. (2020).
- 808 42. Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation network
809 analysis. *BMC Bioinformatics* **9**, 1–13 (2008).
- 810 43. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in
811 multidimensional genomic data. *Bioinformatics* **32**, 2847–2849 (2016).
- 812 44. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. Circlize implements and enhances
813 circular visualization in R. *Bioinformatics* **30**, 2811–2812 (2014).
- 814 45. Xia, J., Wishart, D. S. & Valencia, A. MetPA: A web-based metabolomics tool for pathway
815 analysis and visualization. in *Bioinformatics* vol. 27 2342–2344 (Oxford University Press,
816 2011).
- 817 46. Chong, J. *et al.* MetaboAnalyst 4.0: Towards more transparent and integrative
818 metabolomics analysis. *Nucleic Acids Res.* **46**, W486–W494 (2018).
- 819 47. Kamburov, A., Cavill, R., Ebbels, T. M. D., Herwig, R. & Keun, H. C. Integrated pathway-
820 level analysis of transcriptomics and metabolomics data with IMPaLA. *Bioinformatics* **27**,
821 2917–2918 (2011).
- 822 48. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic*
823 *Acids Research* vol. 28 27–30 (2000).
- 824 49. Kanehisa, M., Sato, Y., Furumichi, M., Morishima, K. & Tanabe, M. New approach for
825 understanding genome variations in KEGG. *Nucleic Acids Res.* **47**, D590–D595 (2019).
- 826 50. Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M. KEGG:
827 Integrating viruses and cellular organisms. *Nucleic Acids Res.* **49**, D545–D551 (2021).
- 828 51. Chang, W., Cheng, J., Allaire, J., Xie, Y. & McPherson, J. shiny: Web Application
829 Framework for R. (2019).
- 830 52. Chang, W. & Borges Ribeiro, B. shinydashboard: Create Dashboards with ‘Shiny’. (2018).
- 831 53. Granjon, D. shinydashboardPlus: Add More ‘AdminLTE2’ Components to
832 shinydashboard. (2020).
- 833 54. Sievert, C. *Interactive Web-Based Data Visualization with R, plotly, and shiny*. (Chapman
834 and Hall/CRC, 2020).

- 835 55. Xie, Y., Cheng, J. & Tan, X. DT: A Wrapper of the JavaScript Library 'DataTables'.
836 (2020).
- 837 56. Attali, D. shinyjs: Easily Improve the User Experience of Your Shiny Apps in Seconds.
838 (2018).
- 839 57. Vaidyanathan, R. & Xie, Y. htmlwidgets: HTML Widgets for R. (2019).
- 840 58. Neuwirth, E. RColorBrewer: ColorBrewer Palettes. (2014).
- 841 59. Zhu, H. kableExtra: Construct Complex Table with 'kable' and Pipe Syntax. (2019).
- 842 60. Wickham, H., Francois, R., Henry, L. & Muller, K. dplyr: A Grammar of Data Manipulation.
843 (2020).
- 844 61. González-Domínguez, R., García-Barrera, T. & Gómez-Ariza, J. L. Metabolite profiling for
845 the identification of altered metabolic pathways in Alzheimer's disease. *J. Pharm.*
846 *Biomed. Anal.* **107**, 75–81 (2015).
- 847 62. Wang, R. & Reddy, P. H. Role of Glutamate and NMDA Receptors in Alzheimer's
848 Disease. *Journal of Alzheimer's Disease* vol. 57 1041–1048 (2017).
- 849 63. Liu, H., Harrell, L. E., Shenvi, S., Hagen, T. & Liu, R. M. Gender differences in glutathione
850 metabolism in Alzheimer's disease. *J. Neurosci. Res.* **79**, 861–867 (2005).
- 851 64. Snowden, S. G. *et al.* Neurotransmitter Imbalance in the Brain and Alzheimer's Disease
852 Pathology. *J. Alzheimer's Dis.* **72**, 35–43 (2019).
- 853 65. Zhao, J. *et al.* A comprehensive metabolomics investigation of hippocampus, serum, and
854 feces affected by chronic fluoxetine treatment using the chronic unpredictable mild stress
855 mouse model of depression. *Sci. Rep.* **9**, 1–11 (2019).
- 856 66. Huo, Z. *et al.* Brain and blood metabolome for Alzheimer's dementia: findings from a
857 targeted metabolomics analysis. *Neurobiol. Aging* **86**, 123–133 (2020).
- 858 67. Kim, S. *et al.* PubChem 2019 update: Improved access to chemical data. *Nucleic Acids*
859 *Res.* **47**, D1102–D1109 (2019).
- 860 68. Wishart, D. S. *et al.* HMDB: The human metabolome database. *Nucleic Acids Res.* **35**,
861 (2007).
- 862 69. Gordon, B. A. *et al.* Tau PET in autosomal dominant Alzheimer's disease: relationship
863 with cognition, dementia and other biomarkers. *Brain* **142**, 1063–1076 (2019).

- 864 70. Peña-Bautista, C. *et al.* Plasma alterations in cholinergic and serotonergic systems in
865 early Alzheimer Disease: Diagnosis utility. *Clin. Chim. Acta* **500**, 233–240 (2020).
- 866 71. Graham, S. F. *et al.* Untargeted metabolomic analysis of human plasma indicates
867 differentially affected polyamine and L-Arginine metabolism in mild cognitive impairment
868 subjects converting to alzheimer’s disease. *PLoS One* **10**, (2015).
- 869 72. Mahajan, U. V. *et al.* Dysregulation of multiple metabolic networks related to brain
870 transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic
871 and transcriptomic study. *PLoS Med.* **17**, e1003012 (2020).
- 872 73. Hamada-Kanazawa, M. *et al.* β -citryl-L-glutamate acts as an iron carrier to activate
873 aconitase activity. *Biol. Pharm. Bull.* **34**, 1455–1464 (2011).
- 874 74. Lewis, E. D., Meydani, S. N. & Wu, D. Regulatory role of vitamin E in the immune system
875 and inflammation. *IUBMB Life* **71**, 487–494 (2019).
- 876 75. Freedman, J. E., Farhat, J. H., Loscalzo, J. & Keaney Jr., J. F. alpha-tocopherol inhibits
877 aggregation of human platelets by a protein kinase C-dependent mechanism. *Circulation*
878 **94**, 2434–2440 (1996).
- 879 76. Freedman, J. E. & Keaney Jr., J. F. Vitamin E Inhibition of Platelet Aggregation Is
880 Independent of Antioxidant Activity. *J. Nutr.* **131**, 374S-377S (2001).
- 881 77. Akanmu, D., Cecchini, R., Aruoma, O. I. & Halliwell, B. The antioxidant action of
882 ergothioneine. *Arch. Biochem. Biophys.* **288**, 10–16 (1991).
- 883 78. Halliwell, B., Cheah, I. K. & Tang, R. M. Y. Ergothioneine - a diet-derived antioxidant with
884 therapeutic potential. *FEBS Lett.* **592**, 3357–3366 (2018).
- 885 79. Tang, R. M. Y., Cheah, I. K.-M., Yew, T. S. K. & Halliwell, B. Distribution and
886 accumulation of dietary ergothioneine and its metabolites in mouse tissues. *Sci. Reports*
887 *2018* **8**, 1–15 (2018).
- 888 80. Cheah, I. K., Feng, L., Tang, R. M. Y., Lim, K. H. C. & Halliwell, B. Ergothioneine levels in
889 an elderly population decrease with age and incidence of cognitive decline; a risk factor
890 for neurodegeneration? *Biochem. Biophys. Res. Commun.* **478**, 162–167 (2016).
- 891 81. Yang, N. C. *et al.* Ergothioneine protects against neuronal injury induced by β -amyloid in
892 mice. *Food Chem. Toxicol.* **50**, 3902–3911 (2012).
- 893 82. Cirrito, J. R. *et al.* Serotonin signaling is associated with lower amyloid- β levels and

- 894 plaques in transgenic mice and humans. *Proc. Natl. Acad. Sci.* **108**, 14968–14973
895 (2011).
- 896 83. Cirrito, J. R. *et al.* Effect of escitalopram on A β levels and plaque load in an Alzheimer
897 mouse model. *Neurology* **95**, e2666–e2674 (2020).
- 898 84. Sheline, Y. I. *et al.* Effect of escitalopram dose and treatment duration on CSF A β levels
899 in healthy older adults. *Neurology* **95**, e2658–e2665 (2020).
- 900 85. Schroeder, S. *et al.* Dietary spermidine improves cognitive function. *Cell Rep.* **35**, (2021).
- 901 86. Liang, Y. T. *et al.* eIF5A hypusination, boosted by dietary spermidine, protects from
902 premature brain aging and mitochondrial dysfunction. *Cell Rep.* **35**, (2021).
- 903

Table 1. Summary statistics for the six datasets included in this study

		Braak (Tau)							CDR				
Condition		N	Age*	%Fe	%APOE4+	0-III	IV-VI	Not avail.	<=0.5	1-2	3	PMI	
Discovery	WUSM (parietal brain)	ADAD	25	54 ± 13.9	32%	36%	0	20	5	0	0	25	13.3
		sAD	305	84 ± 8.8	62%	56%	23	195	87	0	23	282	12.5
		TREM2	21	84 ± 7.5	52%	57%	3	12	6	0	1	20	14.1
		Presymptomatic	15	87 ± 9.7	60%	53%	3	8	4	15	0	0	13.6
		Control	26	88 ± 9.1	69%	12%	20	1	5	26	0	0	10.0
Replication	ROSMAP (DLPFC brain Metabolon)	sAD	233	89 ± 2.9	73%	38%	15	218	0				8.1
		Control	94	86 ± 4.7	59%	10%	94	0	0				7.7
	ROSMAP (DLPFC brain p180)	sAD	43	88 ± 2.8	19%	29%	3	40	0				9.6
		Control	23	87 ± 3.8	35%	7%	23	0	0				8.7
	ROSMAP (serum)	sAD	36	87 ± 3.8	81%	8%							
		Control	55	87 ± 4.4	69%	0%							
	ADNI1 (serum)	sAD	184	75 ± 7.5	48%	66%							
		Control	224	76 ± 5.0	48%	27%							
	ADNI2GO (serum)	sAD	137	74 ± 8.2	42%	66%							
		Control	181	73 ± 6.4	51%	28%							

sAD = Sporadic Alzheimer Disease; CDR = Clinical Dementia Rating; PMI= post mortem interval

*Age is age at death for brain samples, and age at baseline for serum samples.

Table 2. Effects, p-values, and q-values for 16 metabolites which were significant after FDR correction in the ADAD vs CO comparisons and at least nominally significant in the AD vs CO and TREM2 vs CO comparisons in the WUSM cohort. Highlighted in bold are metabolites with significant Q values in the AD vs CO or TREM2 vs CO comparisons.

Metabolite	ADAD vs CO			sAD vs CO			TREM2 vs CO			ROSMAP (DLPFC Metabolon)		
	Effect	p-value	q-value	Effect	p-value	q-value	Effect	p-value	q-value	Effect	p-value	q-value
aspartate	0.160	1.1x10 ⁻³	1.1x10 ⁻²	0.085	2.2x10 ⁻³	9.8x10 ⁻²	0.123	6.0x10 ⁻³	0.27	0.042	1.1x10 ⁻²	5.4x10 ⁻²
γ-glutamylthreonine	0.263	3.2x10 ⁻³	2.3x10 ⁻²	0.171	5.4x10 ⁻⁴	5.5x10 ⁻²	0.278	7.1x10 ⁻⁴	0.11	0.095	5.1x10 ⁻⁴	5.4x10⁻³
β-citrylglutamate	-0.217	4.9x10 ⁻⁵	2.2x10 ⁻³	-0.148	2.1x10⁻⁴	3.6x10⁻²	-0.293	7.8x10⁻⁷	4.9x10⁻⁴	-0.062	3.7x10 ⁻⁴	4.2x10⁻³
glutamate	0.086	7.1x10 ⁻³	3.9x10 ⁻²	0.048	1.7x10 ⁻²	0.36	0.071	6.5x10 ⁻³	0.27	0.060	1.1x10 ⁻⁸	1.4x10⁻⁶
N-acetylglutamate	-0.207	1.7x10 ⁻⁵	1.0x10 ⁻³	-0.080	2.7x10 ⁻³	9.8x10 ⁻²	-0.122	3.2x10 ⁻³	0.19	-0.033	6.8x10 ⁻⁴	6.7x10⁻³
ergothioneine	-0.255	8.3x10 ⁻³	4.3x10 ⁻²	-0.213	8.0x10⁻⁵	2.5x10⁻²	-0.274	7.5x10 ⁻³	0.27	-0.092	2.5x10 ⁻²	0.10
3-hydroxy-2-ethylpropionate	0.177	2.0x10 ⁻³	1.7x10 ⁻²	0.099	4.4x10 ⁻²	0.49	0.195	8.7x10 ⁻³	0.27			
1,5-anhydroglucitol (1,5-AG)	0.310	6.6x10 ⁻⁶	7.3x10 ⁻⁴	0.131	1.1x10 ⁻²	0.27	0.155	4.3x10 ⁻²	0.47	0.088	4.4x10 ⁻³	2.8x10⁻²
2-methylcitrate/homocitrate	-0.171	1.3x10 ⁻³	1.2x10 ⁻²	-0.087	1.3x10 ⁻²	0.30	-0.118	2.9x10 ⁻²	0.41	-0.048	1.1x10 ⁻²	5.4x10 ⁻²
glutarate (C5-DC)	0.252	7.3x10 ⁻⁵	2.3x10 ⁻³	0.121	5.7x10 ⁻³	0.17	0.170	1.6x10 ⁻²	0.35	0.090	1.5x10 ⁻⁵	4.0x10⁻⁴
CDP-choline	-0.095	9.6x10 ⁻⁴	1.0x10 ⁻²	-0.040	4.6x10 ⁻²	0.49	-0.093	1.6x10 ⁻³	0.14	0.042	7.5x10 ⁻³	4.1x10⁻²
CDP-ethanolamine	-0.102	6.1x10 ⁻⁴	7.7x10 ⁻³	-0.054	2.8x10 ⁻³	9.9x10 ⁻²	-0.128	1.8x10⁻⁴	3.7x10⁻²	-0.024	8.2x10 ⁻²	0.23
glycerophosphoinositol	-0.164	3.4x10 ⁻⁴	5.3x10 ⁻³	-0.095	1.3x10 ⁻³	8.0x10 ⁻²	-0.098	2.7x10 ⁻²	0.41	-0.021	4.5x10 ⁻²	0.15
nicotinamide (vitamin B3)	-0.066	6.8x10 ⁻³	3.7x10 ⁻²	-0.032	1.9x10 ⁻²	0.36	-0.056	9.4x10 ⁻³	0.27	0.008	0.33	0.56
α-tocopherol (vitamin E)	-0.120	4.1x10 ⁻⁵	2.0x10 ⁻³	-0.065	1.5x10 ⁻³	8.0x10 ⁻²	-0.115	1.8x10⁻⁵	5.6x10⁻³	-0.123	3.0x10 ⁻⁵	5.7x10⁻⁴
retinol (Vitamin A)	-0.287	1.3x10 ⁻⁵	9.2x10 ⁻⁴	-0.156	8.0x10 ⁻⁴	5.6x10 ⁻²	-0.192	1.4x10 ⁻³	0.14	-0.196	2.9E-04	3.7x10⁻³




Figure 1. Study design. Parietal cortical tissue from donors to the Knight ADRC and DIAN were analyzed on the Metabolon Precision Metabolomics platform: autosomal dominant AD (ADAD, n=25), sporadic AD (sAD, n=305), TREM2 (n=21), Presymptomatic (n=15), and healthy control (CO, n=26). After quality control, 627 metabolites were tested for differential abundance via linear modeling. A metabolic profile was generated from 16 metabolites in common between groups. Pathway analysis was performed on the differentially abundant metabolites, and a web browser was created to share the data and results. Findings were validated in five independent datasets: dorsolateral prefrontal cortex (DLPFC) tissue from the ROSMAP cohort analyzed on the Metabolon platform (sAD n=233, CO n=94), as well as four datasets quantified using the Biocrates p180 platform: DLPFC from the ROSMAP cohort (sAD=43, CO=23), serum from the ROSMAP cohort (sAD n=36, CO n=55), serum from the ADNI1 cohort (sAD n=184, CO n=224), and serum from the ADNI2GO/2 cohort (sAD n=137, CO n=181). The ROSMAP Metabolon dataset was found to have 506 metabolites in common with the Knight ADRC/DIAN cohort after quality control. The p180 platform was found to have 85 metabolites in common with the Metabolon platform.




Figure 2. Association analysis in WUSM dataset. Volcano plots for A) sAD vs CO, B) ADAD vs CO, C) TREM2 vs CO. D) Venn diagram. Box plots for abundance of top metabolites E) β -citrylglutamate, F) α -tocopherol, G) ergothioneine, H) N-acetylputrescine.




Figure 3. Metabolic profile consisting of 16 metabolites which passed FDR correction in ADAD vs CO and were at least nominally significant in sAD vs CO and TREM2 vs CO. A) Heatmap showing relative abundance for each metabolite in the profile. Participants are divided by disease status group: healthy controls (CO), neuropathology but no cognitive impairment (Presymptomatic), sporadic AD (sAD), carriers of TREM2 risk variants (TREM2) and carriers of Mendelian mutations (ADAD). The 30 Early-Stage AD (ESAD) individuals identified by hierarchical clustering are indicated within the red box. Annotations show Clinical Dementia Rating and Braak scores for Tau accumulation. B) Comparison of effects for the 16 metabolites in each model. The x-axis shows the effect of each metabolite in the ADAD vs CO model, while the y-axis shows the effects in the sAD vs CO (blue) and TREM2 vs CO (red) models. C) Boxplot showing distribution of the first principal component for the 16-metabolite profile among each of the status groups.




Figure 4. Distribution of metabolic eigenmetabolite profile between clinical diagnosis groups calculated with 15 metabolites on ROSMAP Metabolon data. 3-hydroxy-2-ethylpropionate was not included because it did not pass quality control in the ROSMAP dataset.